Phase 0, single-arm, open-label “First in Human Study of NU 0129 (spherical nucleic acid gold nanoparticle targeting siRNA targeted to BCL2L12 gene) in recurrent glioblastoma/gliosarcoma”Primary endpoints—safety, feasibility of i.v. administration (monitored during infusion and post-surgery)Status: Phase 0 completed. Ongoing long-term follow-up up to 2 years for survival and safety. This evidence concerns the gene BCL2L12 and glioblastoma.